Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) is closely associated with insulin resistance and gut microbiota dysbiosis. Here, we identified a microbiota-associated indole-3-carboxaldehyde (ICA)-AhR-GLP-1 pathway that contributes to the glucose-lowering effect of sesamin (Ses), a major sesame lignan. In db/db mice, Ses improved hyperglycemia and insulin resistance, while remodeling the gut microbiota and enriching Ligilactobacillus. Fecal microbiota transplantation from Ses-treated donors partially transferred these metabolic benefits. Integrated bacterial isolation, Ses-based fermentation, fecal metabolomics, and clinical LC-MS/MS analysis identified ICA as a Ses-responsive microbiota-associated metabolite. Serum ICA levels were reduced in newly diagnosed patients with T2DM and negatively correlated with FBG, HbA1c, and HOMA-IR. Oral ICA reproduced key metabolic effects of Ses and enhanced intestinal Gcg expression and GLP-1 production. Mechanistically, ICA bound to AhR, promoted AhR nuclear translocation, increased AhR occupancy at the XRE-containing region of the Gcg promoter, and stimulated GLP-1 secretion in STC-1 cells and intestinal organoids. AhR inhibition reduced Ses-induced GLP-1 production and partially attenuated its metabolic effects, whereas acute GLP-1R blockade blunted Ses- and ICA-induced improvements in glucose tolerance and early insulin secretion. Together, these findings support a model in which Ses improves glucose homeostasis in association with gut microbiota remodeling and engagement of an ICA-AhR-GLP-1 pathway.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: